News from ACC.25: oral semaglutide in high-risk DM2

ACC Darren McGuire

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Low-dose apixaban noninferior to full dose in cancer-associated VTE
Low-dose apixaban noninferior to full dose in cancer-associated VTE
ACC.25
Low-dose apixaban noninferior to full dose in cancer-associated VTE
- Diego Sadler, MD
Dapagliflozin reduces worsening HF in elderly TAVI patients
Dapagliflozin reduces worsening HF in elderly TAVI patients
ACC.25
Dapagliflozin reduces worsening HF in elderly TAVI patients
- Wayne Batchelor, MD
Secondary prevention strategy led by nurses reduces MACE risk after an ACS
Secondary prevention strategy led by nurses reduces MACE risk after an ACS
ACC.25
Secondary prevention strategy led by nurses reduces MACE risk after an ACS
- Giulia Magnani, MD, PhD
Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
ACC.25
Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
- Gina Lundberg, MD